ロード中...
Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions
Ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, was the first therapy demonstrated to improve overall survival in melanoma. Since ipilimumab’s approval by the FDA in 2011, a wealth of data have amassed, helping clinicians to optimize its use. We have learned how to mitigate the advers...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3799873/ https://ncbi.nlm.nih.gov/pubmed/23933888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11912-013-0337-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|